Navigation Links
Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
Date:1/10/2011

FLORHAM PARK, N.J., Jan. 10, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.  KAPVAY™ is the first and only FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication, in addition to use as monotherapy.

"Shionogi is extremely proud to bring KAPVAY™ to market in the U.S.," said Donald C. Manning, MD, PhD, Chief Medical Officer of Shionogi Inc.  "The extended-release version of clonidine hydrochloride found in KAPVAY™ offers an exciting new treatment option for children and adolescents with ADHD who are not experiencing adequate symptom relief from stimulants alone."  

ADHD affects more than 4.5 million children in the U.S., with at least 7 percent of U.S. school-aged children believed to suffer from the condition.  Symptoms include difficulty in maintaining attention and focus and in controlling behavior, as well as hyperactivity/over-activity.  While stimulant medications remain a first line treatment for ADHD, up to 30 percent of ADHD patients do not achieve an optimal response to stimulant monotherapy.

KAPVAY™'s recent FDA approval was based on two Phase III studies, which demonstrated significant efficacy at Week 5 in children and adolescents (6-17 years) with ADHD treated with KAPVAY™.  Signs and symptoms of ADHD were evaluated using the investigator administered and scored ADHD Rating Scale-IV-Parent Version (ADHDRS-IV) total score, including hyperactive/impulsivity and inattentive subscales.  Treatment-emergent adverse events, such as somnolence and fatigue, were mostly mild to moderate. Thirteen percent (13%) of patients
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
6. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Inc. (Nasdaq: BMRN ) today announced that Joshua ... will present a company update at the Deutsche Bank 2010 ... 9:00 a.m. ET.   Interested parties may access ... investor section of the BioMarin website, www.BMRN.com .  A ...
... Dec. 6, 2010 SI-BONE, Inc. (San Jose, California), a ... minimally invasive surgical (MIS) device to treat the sacroiliac (SI) ... Institute, has joined its Medical Advisory Board (MAB). Dr. Rashbaum ... and Nick Shamie, along with SI-BONE founder, Mark Reiley, on ...
Cached Medicine Technology:BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 3SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 4
(Date:7/11/2014)... 11, 2014 Microbiology testing is a ... diagnostics industry, which is expected to pose the biggest ... sector owes its growth to the ongoing spread of ... worldwide and a major factor leading to the upsurge ... bio-terrorism, and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... , RICHMOND, Calif., Aug. 18 Transcept ... to reduce operating expenses by eliminating certain staff positions following ... Products to commercialize Intermezzo ((R) )(zolpidem tartrate sublingual tablet) ... Glenn A. Oclassen, President and Chief Executive Officer commented, ...
... SAN DIEGO, Aug. 18 Aethlon Medical, ... present at today,s 14th Annual Southern California Investor Conference ... California. The conference is hosted by California Equity Research ... world-recognized life science, technology, media, and real estate/financial organizations. ...
... ... today announced that the hemostatic HemCon Patch™ and HemCon® Bandage ... with Premier Purchasing Partners L.P., the group purchasing unit of Premier ... 2011. The agreement makes HemCon dressings available at pre-negotiated terms to ...
... , INDIANAPOLIS, Aug. 18 "If commercial flying ... fire, there would be a public revolt," said Rob Schnepp, CPTC ... Fire Department in California. "The numbers aren,t going down, and this ... NFPA study reveals 87-percent of people who died in fires had ...
... ... States Health Alliance Admitted to Talent Management Organization , ... Atkins, VA (PRWEB) August 18, 2009 -- The ... world-class companies, has two new members, Qwest, headquartered in Denver, Colorado, and Mountain States ...
... , ... Group (ISG), a nationwide network of identification and card issuance sales and service experts, ... the Medical Group Management Association (MGMA). , ... Kansas City, MO (PRWEB) August 18, 2009 -- Identification Systems ...
Cached Medicine News:Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 2Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 3Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 4Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 5Health News:Aethlon Medical to Present at Today's Southern California Investor Conference 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 3Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 2Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 2Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 4Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 2Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 3
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... the typical patient, right for the not-so-typical ... you have the ability to address the ... least expect themeven after implant. St. Jude ... to be prepared in almost any situation, ...
... Right for the typical patient, right ... Medical ICDs, you have the ability to ... when you least expect themeven after implant. ... you need to be prepared in almost ...
... Based Nursery ID and Visitor Control System. A ... hospital to compare and verify identity of those ... It helps document interactions with all visitors and ... a given child patient. It also helps to ...
Medicine Products: